Solution-Phase Parallel Synthesis of a 1,2,7-Trialkyl-1H-imidazo[4,5-g]quinoxalin-6-ol Library Scaffold

Abstract

This paper describes solution-phase parallel synthesis of a library with a novel 1,2,7-trialky-1H-imidazo[4,5-g]quinoxalin-6-ol scaffold and three points of diversity. The library is prepared using 1,5-difluoro-2,4-dinitrobenzene as the starting material and commercially available chemicals as the building blocks. A new, inexpensive, and practical apparatus for parallel filtration is also described.

Molecular Characteristics of CTA056, a Novel Interleukin-2-Inducible T-Cell Kinase Inhibitor that Selectively Targets Malignant T Cells and Modulates Oncomirs

“…The synthetic approach of CTA056 is similar to that reported previously (Zhang et al, 2005), but with slight modification as shown in Fig. 1A.…”

Identification of Peptide Substrate and Small Molecule Inhibitors of Testis-Specific Serine/Threonine Kinase1 (TSSK1) By the Developed Assays

“…Compounds with 14 different chemical skeletons (Figure a) were in stock in our laboratory as 50 mM solutions. These compounds were assembled through a scaffold-directed program, aimed at developing benzofused privileged structures with druglike properties. − A total of 640 single pure compounds were screened with initial concentration of 20 μM (see Supporting Information). Among them, eight compounds showed reproducible inhibitory activity (>40%) and two of them, 5-hydroxy-8-methyl-4-propyl-7,8-dihydropyrano[3,2-g]chromene-2,6-dione ( 7 ) and 1,1′-(biphenyl-4,4′-diyl)bis(2,2-dihydroxyethanone) ( 8 ), had measured IC 50 values of 38.7 μM and 43.2 μM, respectively (Figure b).…”

“…The incorporation of two privileged pharmacophores may provide additional opportunities to discover novel lead compounds using one synthetic process. A chemical library of 1,2,7-trialky-1 H -imidazo[4,5- g ]quinoxalin-6-one was designed and synthesized by our laboratory to integrate benzimidazole and quinoxalin-2-one privileged structures into one molecule . This library was composed of five mixed analogues per well, and the total purity of five compounds/well is >80% by HPLC analysis (UV wavelength at 254 nm).…”

Identification of 3,5,6-substituted indolin-2-one’s inhibitors of Aurora B by development of a luminescent kinase assay

“…Our compound collection were assembled through a scaffold-directed program aiming at developing benzofused heterocyclic privileged structures with drug-like properties. [18][19][20][21][22][23][24][25][26][27][28][29] Thirteen compounds were greater than 60% inhibition of Aurora B activity under the concentration of 10 lM in the primary screening. Two of them were at 3.3 lM (13-39) and 8.2 lM (13-15) with 50% inhibition of Aurora B (Fig.…”